A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models
Pär Larsson(Swedish Defence Research Agency), Malin Flodström‐Tullberg(Karolinska University Hospital), Renata Utorova(Karolinska University Hospital), Pascal Chaux(Sanofi (France)), S. Jacobson(Karolinska University Hospital), Tadepally Lakshmikanth(Hammersmith Hospital), Erna Domsgen(Karolinska University Hospital), Mikael Knip, Valérie Lecouturier(Sanofi (France)), Maarit Oikarinen(Tampere University), Jeffrey W. Almond(Sanofi (France)), Nicolas Devard(Sanofi (France)), Olli H. Laitinen(Tampere University), Minni R. L. Koivunen, Heikki Hyöty(Tampere University)
Cited by 43
Related Papers
The complete genome sequence of Francisella tularensis, the causative agent of tularemia
|Nature Genetics|2005|448